Drug Clinical Trials List
Drug Clinical Trials List
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| The Effectiveness of Convalescent Plasma for the Treatment of Severe COVID-19 Cases in Intensive Care Unit | King Faisal Specialist Hospital and Research Centre | Ongoing | Convalescent Plasma | 3 | IRB 2020-19-V2 | KFSH&RC-J |
| The effect of Zamzam water on the immunity of healthy university students in the eastern province of Saudi Arabia | PI initiated | Completed | Zamzam water | 2 | IRB-2020-01-393 | Imam Abdulrahman Al Faisal Hospital (Riyadh) |
| The Effect of Rectal Progesterone on the Latency period as well as Maternal and Prenatal Outcome in PPROM Between 24-33+6 Weeks | Umm Al Qura University | Ongoing | Progesterone | 3 | ISRCTN65694106 | UQU |
| The effect of cinnamon supplementation on ovulation induction in women with polycystic ovary syndrome, Jeddah 2018: Randomized Double-Blind Placebo-controlled trial | Dr. Wael Alzhrani (PI-initiated) | Ongoing | Cinnamon | 3 | 100-18 | KAUH-J |
| The effect of (Oligonol) and (Oligonol + metformin) on the components of Metabolic Syndrome in obese individuals- A randomized, double-blind, factorial clinical trial. | Amino Up Chemical Co., Ltd. | Terminated | Oligonol | 3 | SDRG- Amino Up 1 | KFMRC-J |
| Superiority of Insulin Glargine Lantus vs. NPH: Treat to Normoglycemia Concept.Effect of Insulin Glargine in Comparison to Insulin NPH in Insulin-nave People With Type 2 Diabetes Mellitus Treated With at Least One OAD and Not Adequately Controlled | Sanofi | Completed | Lantus® | 3 | LANTU_C_02762 | KFUH |
| "Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy" | Inovio Pharmaceuticals, Inc. | Completed | NO-4700 + CELLECTRA™ 2000 (device) | 2 | MERS-201 | KSMC |
| Study of Aflibercept in Uveitic Macular EDema (SAUD study) | King Khalid Specialist Hospital | Rejected | Aflibercept | 3b | 18176 | KKESH |
| "Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" | Eli Lilly | Ongoing | Dulaglutide 0.75 /1.5 mg | 3 | H9X-MC-GBGC | KKUH |
| Standard Induction with Basiliximab versus No-Induction in Low Immunological Risk Kidney Transplant Recipients Prospective Randomized Double Blind Controlled Clinical Trial | King Faisal Specialist Hospital and Research Centre | Ongoing | BASILIXIMAB (SIMULECT) | 3 | 2191177 | King Faisal Specialist Hospital and Research Center (Riyadh) |